 
 |
With over 90 years of scientific and operational expertise in biotechnology, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, arrange licensing agreements and strategic alliances, recruit key management personnel, and acquire new products and technology to accelerate growth. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices. Jaro BioSciences |
News & Events
SPECTRAGENICS ANNOUNCES $30M IN NEW FUNDING CHANGES COMPANY NAME TO TRIA BEAUTY AVANIR to Raise $40.0 Million to Fund Zenvia Through Clinical Development and Regulatory Approval Carbylan Announces $20 Million Series B Financing Yaupon Therapeutics closes $14.5 million financing -- Series C financing positions company to advance development of its product portfolio targeting cancer and central nervous system diseases BioForm Announces Pricing of Initial Public Offering Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence APT Pharmaceuticals Closes New $22 Million Funding Round Sagent Pharmaceuticals Inc. Completes $53M Series A Financing Acura Pharmaceuticals, Inc. secures financing to fund pivotal Phase III clinical trial for lead Aversion® technology product candidate Capnia names chairman, CEO Biodel Inc. Announces Completion of Public Offering Vivo Ventures Announces the Closing of Vivo Ventures Fund VI, a $275M Life Science Venture Fund TransOral Pharmaceuticals Raises $40 Million in Series D Financing Synapse BioMedical Completes Series C Private Equity Financing InteKrin Therapeutics Secures $23 M Venture Financing Biodel Inc. Raises $21 Million in Series B Financing Naryx Pharma Completes Series B2 Private Equity Financing
|
